UBS Group
HZNP

UBS Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-106,500
Closed -$12.3M – 10588
2023
Q3 		$12.3M Sell
106,500
-317,900
-75% -$34.2M ﹤0.01% 1829
2023
Q2 		$43.6M Buy
+424,400
New +$44.8M 0.01% 910
2015
Q1 		– Sell
-1,000
Closed -$13K – 9705
2014
Q4 		$13K Buy
+1,000
New +$12.5K ﹤0.01% 8171

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's HZNP Position: Q4 2023 in Review

UBS Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 534,044 shares — an estimated $61.8M sold.

UBS Group first reported a position in HZNP in Q4 2014 and held it in 36 quarters. The position peaked at $68.5M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • UBS Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 534,044 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $61.8M.
  • UBS Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 36 quarters.
  • UBS Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $68.5M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.